Brief: Cyclo Therapeutics Presents Positive Data From Clinical Development Program For Lead Candidate, Trappsol Cyclo, At WORLDSymposium 2021
09/02/2021 13:12
Feb 9 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS PRESENTS POSITIVE DATA FROM CLINICAL
DEVELOPMENT PROGRAM FOR LEAD CANDIDATE, TRAPPSOL® CYCLO™, AT
WORLDSYMPOSIUM 2021
* CTD HOLDINGS INC - PHASE 1 BIOMARKER
24S-HYDROXYCHOLESTEROL
DEMONSTRATES CLEARANCE OF EXCESS CHOLESTEROL FROM BRAIN AFTER
INTRAVENOUS INFUSIONS
* CTD HOLDINGS INC - INTERIM ANALYSIS OF PHASE 1/2 STUDY
SHOWS
TRAPPSOL(®) CYCLO™ TO HAVE FAVORABLE SAFETY PROFILE AND
ENCOURAGING SIGNALS IN EFFICACY
Source text for Eikon: ID:nBw7kSDZpa
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug